DocumentsDate added
RESEARCH ARTICLE
Mustafa Abdelgadir Khandgawi Ibrahim*,Adel Nasr Morsi,Liza Hamdi Mohamed
Department of Chemical Pathology, Faculty of Medical Laboratory Sciences, University of Khartoum, Sudan
Address reprint requests to
*Mustafa Abdelgadir Khandgawi Ibrahim,
Department of Chemical Pathology,Faculty of Medical Laboratory Sciences, Sudan, Khartoum
Article citation: Ibrahim MAK, Morsi AN, Mohamed, LH. Lipid profiles in Sudanese women with polycystic ovary syndrome. J Pharm Biomed Sci 2016;06(05):301–303.Available at www.jpbms.info
ABSTRACT
Background Polycystic ovary syndrome (PCOS) has been one of the important public health problems in Sudan, which leads to medical consequences and ends up in sterility.
Methods This study includes 40 PCOS women with age ranged between 16 and 40 years were selected based on Rotterdam criteria 2003 and 40 ovulatory normal non-PCOs, healthy and age-matched women as control. The lipid profiles (total cholesterol, LDL-C, HDL-C and triglyceride [TG]) were measured by an enzymatic colorimetric method using biosystem reagents. The data management and analysis were done with SPSS version 22.
Results There was no significant difference between the two groups in terms of age and body mass index except TG in PCOS ladies with BMI more than 25 was significantly higher in comparison with non-PCOs.
Conclusion This study does not guide the belief that PCOS affects serum lipid ranges, besides in the term of TG in PCOS girls with BMI >25. It is far advised to do this study in ladies with PCOS sufferers from insulin resistance.
KEYWORDS lipid profiles, PCOS, Sudanese women
References:
1.Iuhas C, Costin N, Mihu D. Lipid parameters in patients with polycystic ovary syndrome. Appl Med Informatics. 2012;31(4):27–32.
2.Allahbadia GN, Merchant R. Polycystic ovary syndrome and impact on health. Middle East Fertil Soc J. 2011;16(1):19–37.
3.Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002;26(7):883–96.
4.Swetha N, Vyshnavi R, Modagan P, Rajagopalan B. A correlative study of biochemical parameters in polycystic ovarian syndrome. Int J Biol Med Res. 2013;4:3148–54.
5.Iuhas CI, Costin N, Mihu D. Lipid parameters in patients with polycystic ovary syndrome. Appl Med Inform Origin Res.2012;31:27–32.
6.Rizzo M, Berneis K, Carmina E, Rini GB. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? Am J Obstet Gynecol. 2008;198:28–5.
7.Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case–control study. J Clin Endocrinol Metab. 2008;93:470–6.
8.Amini L, Sadeghi MR, Oskuie F, Kamali K, Maleki H. Lipid profile in women with polycystic ovary syndrome. Crescent J Med Biol Sci. 2014;1(4):147–50.
9.Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb P,et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol. 2005;58:151–4.
10.Swetha N, Vyshnavi R, Modagan P, Rajagopalan B. A correlative study of biochemical parameters in olycystic ovarian syndrome. Int J Biol Med Res. 2013;4:3148–54.
11.Latha M, Bhaskar MV, Sharma SSB, Sumapreethi A. Evaluation of dyslipidemia and oxidative stress in patients with polycystic ovarian syndrome. J Evol Med Dent Sci. 2012;1(5):769–775.
12.Shoaib O, Mustafa S, Nourein I. Serum lipid profile of polycystic ovary syndrome in Sudanese women. Int J Med Sci Public Heal [Internet]. 2015;4(11):1.
13.Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M,et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab. 2003;88:4682–8.
14.Savic S, Zarkovic M, Ciric M, Beleslin B, Drezgic M, Trbojevic B.Lipid profile in normal weight and obese women with polycystic ovary syndrome. Endocr Abstracts. 2006;11:341.
15.Bachceci M, aydemir M, Tuzcu A. Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril. 2007;87:1363–8.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Acknowledgments: The authors are thankful to the respected Prof. Mohamed Tageldin Ibrahim Omer and Dr. Omer Balla Ibrahim for guiding them in statistical analysis.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the study.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Ye Qiumian1†,Ye Xiaocui2†,Luo Rui1†, Ou Jinlai2,Xu Zhenxia1,Zhao Wen1,Li Sha1*
1 Department of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou 510632, China
2 Sunshine Lake Pharma Co., Ltd., Shenzhen 518000, China
† Ye Qiumian, Ye Xiaocui and Luo Rui contributed equally to this work
Address reprint requests to
*Li Sha, Department of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou 510632, China
Article citation: Qiumian Y, Xiaocui Y, Rui L, Jinlai O, Zhenxia X, Wen Z, Sha L. In vitro antifungal activity of pluronic-based thermo-sensitive itraconazole gels for vaginal administration. J Pharm Biomed Sci 2016;06(05):343–346.Available at www.jpbms.info
Abstract:
Vulvovaginal candidiasis (VVC) is a common genital disease disturbing women. ITZ is widely used for the treatment of VVC by oral administration in clinic. Due to its irregular absorption and systematic side effects, local administration of ITZ may be a preferred alternative for VVC treatment. The aim of this study was to investigate the in vitro antifungal activity of pluronic-based thermo-sensitive gels (TSG) of itraconazole (ITZ) for vaginal administration. 3-(4,5-2-yl)-2,5-diphenyltetrazolium bromide method was used to evaluate the antifungal activity of the ITZ-TSG against major microorganisms inducing vulvovaginal candidosis. The gelation temperature of ITZ-TSG was 25 and 35°C before and after the dilution of simulated vaginal fluid. Compared with ITZ, ITZ-TSG demonstrated effective antifungal activity and the gel vehicle showed no action. It suggested that ITZ-TSG may be a good candidate for vulvovaginal candidosis treatment.
KEYWORDS itraconazole, thermosentitive gels, antifungal activity in vitro, vaginal administration.
REFERENCES
1.Keller KA. Therapeutic review. J Exotic Pet Med. 2011;20(2):156–60.
2.Francois M, Snoeckx E, Putteman P, Wouters F, De Proost E,Delaet U, et al. A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS PharmSci. 2003;5(1):50–54.
3.Xiao-cui YE, Jin-lai OU, Bao-xian H, Cui-juan F, Sha L. Preparation and characteristics of itraconazole vaginalthermosensitive in situ gels. J Cent South Pharm. 2014;12(6):551–556.
4.Zhang HH, Luo QH, Yang ZJ, Pan WS, Nie SF. Novel ophthalmic timolol meleate liposomal-hydrogel and its improved local glaucomatous therapeutic effect in vivo. Drug Deliv. 2011;18(7):502–10.
5.das Neves J. Vaginal delivery of biopharmaceuticals. In: das Neves J, Sarmento B (eds). Mucosal delivery of biopharmaceuticals:biology, challenges and strategies, Springer: New York;2014. pp. 261–80.
6.Yi Y, Yoon HJ, Kim BO, Shim M, Kim SO, Hwang SJ, et al. A mixed polymeric micellar formulation of itraconazole: characteristics, toxicity and pharmacokinetics. J Control Release. 2007;117(1):59–67.
7.Odds FC. Itraconazole: a new oral antifungal agent with a very broad spectrum of activity in superficial and systemic mycoses. J Dermatol Sci. 1993;5(2):65–72.
8.Sobel JD, Faro S, Force RW. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178(2):203–211.
9.Sinem Y, Seda R, Zeynep AY, Esra B. A new in-situ gel formulation of itraconazole for vaginal administration. Pharmacol Pharm. 2012;3:417–426.
10.Gupta A, Bluhm R. Itraconazole (Sporanox®) for vulvovaginal candidiasis. Skin Ther lett. 2001;7:1–3.
11.Fang T, Yu-zhu W, Kai Y, Cheng-li W, Qian-qian C, Wei-hua LI, et al. Rheological characteristics of nifeviroc vaginal thermosensitive in situ gels. Chin J New Drugs. 2013;22(3):345–350.
12.Cheng-wei W, Xing T, Xiao-mei W, Xiao-lin T, Zhen LI. Preparation of temperature-sensitive nonoxynol-9 sustained-release gel for vagina. Chin J New Drugs. 2006;15(4):281–284.
13.Puxiang C, Shangrong F. Development in classification, mycology and treatment of vulvovaginal candidiasis. Foreign Med Sci.2005;16(4):235–237.
14.Meletiadis J, Meis JF, Mouton JW, Donnelly JP, Verweij PE.Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl- 2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol. 2000;38(8):2949–54.
15.Genyan L, Wangsheng Z. In vitro drug sensitivity test of pathogenic fungi. J Clin Labor. 2011;06:406–409.
16.Yangjun S. In vitro interaction research of tetrandrine combined with azole antifungal agents. Jinan Univ. 2013.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of support: This research was supported by High Level University Construction Project (88015006).
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research,
patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
Original article
Shanmugasamy K1Sujata Mallick1,Rajendra S. Dhaka1*,Koteeswaran G1,Dhananjay S. Kotasthane1,Seetesh Ghose2
1 Department of Pathology, Mahatma Gandhi Medical College and Research Institute, Pondicherry, 607402, India
2 Department of Obstetrics Gynaecology, Mahatma Gandhi Medical College and Research Institute, Pondicherry, 607402, India
Address reprint requests to
*Dr. Rajendra S. Dhaka, MD PhD, Professor of Pathology Mahatma Gandhi Medical College and Research Institute, Pondicherry, 607402, India
Article citation: Shanmugasamy K, Mallick S, Dhaka RS, Koteeswaran G, Kotasthane DS, Ghose S. Cytomorphological evaluation of 1,000 cases of unhealthy cervix to assess present role of Pap smear screening in developing country. J Pharm Biomed Sci 2016;06(05):269–274.Available at www.jpbms.info
ABSTRACT
Introduction Last few decades saw a Pap smear becoming synonymous with early detection of cervical carcinoma, leading to its rapid decline worldwide. However, newer screening modalities like liquid cytology have been embraced by the developed world. The relevance of the Pap smear in developing countries like India needs to be evaluated.
Objectives To assess the risk factors associated with cervical carcinoma. To correlate cyto-clinical–histopathological findings in the unhealthy cervix by Pap smear to determine its validity and feasibility.
Materials and Methods Pap smears from 1,000 patients who presented in the Gynaecology department with the unhealthy cervix (discharge, bleeding or signs like erosion were clinically grouped as unhealthy) from December 2011 to May 2013 were enrolled in the study. Risk factors for cervical carcinoma were taken into consideration. The cytological results were correlated with the clinical findings and compared to the biopsy results.
Results A total of 114 patients presented with epithelial cell abnormalities in cervical smears, low-grade squamous intraepithelial lesion (LSIL 4.4%) being the most common lesion. Risk factors for malignancy showed significant association with epithelial cell abnormality (P = 0.05%). Cervical smears showing epithelial cell abnormality were significantly associated with the clinical findings like discharge (P = 0.001), erosion (P-value = 0.002) and unhealthy looking cervix (P-value = 0.028). Pap smear showed 59.4% sensitivity, a positive predictive value of 95.4 and 55.9% concordance with the biopsy.
Conclusion Pap smear has moderate sensitivity and high specificity. The feasibility and cost effectiveness of Pap smear to detect cervical cancer in the presence of significant risk factors and unhealthy symptoms makes it an effective screening procedure in the developing countries with limited resources and infrastructure.
KEYWORDS pap smear, cervical carcinoma, unhealthy cervix
REFERENCES
1.Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: cancer incidence,mortality and prevalence worldwide. Lyon: IARC Press.2001. Available at http://www.scielosp.org/scielo.php.
2.Kaur P, Kushtagi P. Plastic spatula with narrow long tip provides higher satisfactory smears for Pap test. J Cytol. 2013;30(3):159–161.
3.World Health Organization (February 2006). Fact sheet No. 297:cancer. 2007. Available at http://www.who.int/mediacentre/factsheets/fs297/en/ index.
4.Mathew A, George PS. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix: worldwide. Asian Pac J Cancer Prev. 2009;10:645–50.
5.Johnson B. Overpopulation problem: lack of resources. 2011.Available at http://www.nationalgeographic.com/eye/overpopulation.
6.Nambaru L, Meenakumari B, Swaminathan R, Rajkumar T. Prognostic significance of HPV physical status and integration sites in cervical cancer. Asian Pac J Cancer Prev. 2009;10:355–60.
7.Parazzini F, Vecchia CL, Negri E, Fedele L, Franceschi S, Gallotta L. Risk factors for cervical intraepithelial neoplasia. Cancer.1992;69:2276–82.
8.Winkelstein W Jr. Smoking and cancer of the uterine cervix:hypothesis. Am J Epidemoil. 1977;106(4):257–9.
9.Wahi PN, Mali S, Luthra UK. Factors influencing cancer of the uterine cervix in north India. Cancer. 1969;23:1221–26.
10.Pradhan N, Giri K, Rana A. Cervical cytology study in unhealthy and healthy looking cervix. N J Obstet Gynecol. 2007;2(2):42–47.
11.Pradhan B, Pradhan SB, Mital VP. Correlation of PAP smear findings with clinical findings and cervical biopsy. Kathmandu Univ Med J. 2007;5(4):461–67.
12.Patel MM, Pandya AN, Modi J. Cervical Pap smear study and its utility in cancer screening, to specify the strategy for cervical cancer control. Nat J Comm Med. 2011;2(1):49–51.
13.Rajani V. Cytopathology of cervix with particular reference to sexually transmitted diseases. MD Thesis. Rangaraya Medical College, N.T.R. Univ. of Health Sciences. Kakinada. 2007.
14.Monalisa P. Cytologic study of epithelial changes in unhealthy cervix: MD Thesis. Aryabhatt Univ Patna. 2013.
15.Pradhan N, Giri K, Rana A. Cervical cytological study in unhealthy and healthy looking cervix. N J Obstet Gynaecol. 2007;2(2):42–47.
16.Nikumbh DB, Nikumbh RD, Dombale VD, Jagtap SV, Desai SR. Cervicovaginal cytology: clinicopathological and social aspect of cervical cancer screening in rural (Maharashtra) India. Int J Health Sci Res. 2012;192:125–32.
17.Jha BM, Patel M, Patel K, Patel J. A study on cervical Pap smear examination in patient living with HIV. Nat J Med Res. 2012;2(1):81–84.
18.Bal MS, Goyal R, Suri AK, Mohi MK. Detection of abnormal cervical cytology in Papanicolaou smears. J Cytol. 2012;29(1):45–47.
19.Thulaseedharan JV, Malil AN, Hakama M, Esmy PO, Cheriyan M, Swaminathan R, et al. Socio demographic and reproductive risk factors for cervical cancer: a large prospective cohort study from rural India. Asian Pac J Cancer Prev. 2012;13:2991–95.
20.Saha R, Thapa M. Correlation of cervical cytology with cervical histology. Kathmandu Univ Med J. 2005;3(3):222–24.
21.Nawaz HF, Aziz AB, Percez S, Rizvi JH. Prevalence of abnormal Papanicolaiu smears and cytohistological correlation: a study from Aga Khan University Hospital, Pakistan. Asian Pac J Clin Oncol. 2005;1:128–132.
22.Jain V, Vyas AS. Cervical neoplasia–cyto-histological correlation (Bethesda system): a study of 276 cases. J Cytol Histol. 2010;1:106.
23.Sherwani RK, Khan T, Akhtar K, Zeba A, Siddiqui FA, Rahman K,Afsan N. Conventional Pap smear and liquid based cytology for cervical cancer screening: a comparative study. J Cytol.2007;15(4):167–172.
24.Afshan N. Role of cytology, colposcopy and colposcopic directed biopsies in the evaluation of unhealthy cervix. MD Thesis. Rajiv Gandhi Univ. of Health Sciences. Bijapur. 2010.
25.Bhatla N, Mukhopadhyay A, Kriplani A, Pandey RM, Patti EG, Shah KV, et al. Evaluation of adjunctive tests for cervical cancer screening in low resource setting. Ind J Cancer. 2007;44(2):51–55.
26.Goel A, Gandhi G, Batra S, Bhambhani S, Zutsi V, Sachdeva P.Visual inspection of the cervix with acetic acid for cervical intraepithelial lesion. Int J Gynecol. 2005;88:25–30.
27.Rao SJ. Trends in cervical cancer screening in developing countries. World J Obstet. 2012;1(4):46–54.
28.Hegde D, Shetty H, Shetty P, Rai S. Diagnostic value of acetic acid comparing with conventional Pap smear in the detection of colposcopic biopsy-proved CIN. J Cancer Res Ther. 2011;7(4):454–58.
29.Sodhani P, Gupta S. Why is high grade squamous intraepithelial neoplasia under-diagnosed on cytology in a quarter of cases?: analysis of smear characteristics in discrepant cases. Indian J Cancer. 2004;41(3):104–8.
30.Khattak ST, Khattak I, Naheed T, Akhtar S, Jamal T. Detection of abnormal cervical cytology by Pap smears. Gomal J Med Sci.2006;4(2):74–77.
31.Ramesh G, Sudha R, Jayashree AK, Padmini J. Colpscopic evaluation of the unhealthy cervix. J Clin Diag Res. 2012;6:1026–28.
32.Banik U, Bhattacharjee P, Ahamad SU, Rahman Z. Pattern of epithelial cell abnormality in Pap smear: a clinicopathological and demographic correlation. J Cytol. 2011;8:8.
33.Moscicki AB, Burt VG, Kanowitz S, Darragh T, Shiboski S. The significance of squamous metaplasia in the development of low grade squamous intraepithelial lesions in young women. Cancer. 1999;85(5):1139–44.
34.Bidus MA, Maxwell GL, Kulasingam S, Rose GS, Elkas JC, Cheronofsky M, et al. Cost effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet Gynecol. 2006;107(5):997–1005.
35.Nandini NM, Nandish SM, Pallavi P, Akshatha SK, Chandrashekhar AP, Anjali S, et al. Manual liquid based cytology in primary screening for cervical cancer: a cost effective preposition for scarce resource settings. Asian Pac J Cancer Prev. 2012;13(8):3645–51.
36.Govt. of Indian, Ministry of Home Affairs. Size, growth rate and distribution of population. 2011. Available at http://www. censusindia.gov.in/cesus_Data_2011/India_at_glance/popul.aspx
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the study.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
RESEARCH ARTICLE
Xiao-Mei Chen,Qing Wang, Rui-Kun He, Yu-Tao Li,Xiao-Yun Chen, Hiroshi Kurihara, Rong-Rong He, Yi-Fang Li*
Institute of Traditional Chinese Medicine and Natural Products, Jinan University,Guangzhou 510632, Guangdong, China
Address reprint requests to
*Yi-Fang Li, PhD, Institute of Traditional Chinese Medicine and Natural Products,Jinan University, Guangzhou 510632,Guangdong, China
Article citation: Chen XM, Wang Q, He RK, Li YT, Chen XY, Kurihara H, He RR,Li YF. Immunomodulating effects of bleomycin and its derivatives, peplomycin and liblomycin on murine antitumour effector cells. J Pharm Biomed Sci 2016;06(05):304–310.Available at www.jpbms.info
ABSTRACT
We investigated the immunomodulating effects of bleomycin and its derivatives, peplomycin and liblomycin on natural killer (NK) cells and lymphokine-activated killer (LAK) precursor cells from the spleens of C57BL/6 mice. Results showed that bleomycin and peplomycin can increase in vitro NK and LAK precursor cell activities both per spleen and per unit number (1 × 106 ) of the spleen cells as compared with normal mice from day 1 to 9,while the number of spleen cells did not increase. Meanwhile, a single administration of liblomycin caused a decrease in the number of spleen cells and the activity of LAK precursor cells per mouse spleen from day 1 and they recovered to normal levels by day 9.
NK activity, which was also suppressed by liblomycin, recovered slowly but failed to reach the complete restoration by day 9. Liblomycin showed no effect on LAK precursor cell activity per unit number of spleen cells. Further study showed that these immunomodulating effects of bleomycin and its derivatives are apparently at least partially mediated by the endogenous cytokine release.
KEYWORDS bleomycin, peplomycin, liblomycin, natural killer cell, lymphokine-activated killer precursor cell, cytokine
References:
1.Cragg GM, Kingston DGI, Newman DJ. Anticancer agents from natural products, 2nd ed., Boca Raton: CRC Press LLC;2005.
2.Abdul Hamied TA, Parker D, Turk JL. Potentiation of release of interleukin-2 by bleomycin. Immunopharmacology. 1986;12(2):127–134.
3.Hillel AT, Samad I, Ma G, Ding D, Sadtler K, Powell JD, et al. Dysregulated macrophages are present in bleomycin-induced murine laryngotracheal stenosis. Otolaryngol Head Neck Surg.2015;153(2):244–250.
4.Xu ZY, Hosokawa M, Morikawa K, Hatakeyama M, Kobayashi H.Overcoming suppression of antitumor immune reactivity in tumor-bearing rats by treatment with bleomycin. Cancer Res.1988;8(23):6658–6663.
5.Williamson JD, Sadofsky LR, Hart SP. The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis. Exp Lung Res. 2015;41(2):57–73.
6.Takita T, Ogino T. Peplomycin and liblomycin, a new analogues of bleomycin. Biomed Pharmacother. 1987;41(5):219–226.
7.Takahashi K, Ekimoto H, Minamide S, Nishikawa K, Kuramochi H, Motegi A, et al. Liblomycin, a new analogue of bleomycin. Cancer Treat Rev. 1987;14(3–4):169–177.
8.Micallef M, Hosokawa M, Shibata T, Nakane A, Yang ZB,Minagawa T, et al. Immunoregulatory cytokine release in rat spleen cell cultures after treatment with bleomycin and its analogues in vivo. Cancer Immunol Immunother. 1991;33(1):33–38.
9.Ryzhkov VK, Zeidlits VN, Tikhonov KB. Use of protamine sulfate as a vasodilator in liver and spleen angiography. Vestn Rentgenol Radiol. 1977;(6):41–45.
10.Dresp J, Schmid E, Bauchinger M. The cytogenetic effect of bleomycin on human peripheral lymphocytes in vitro and in vivo. Mutat Res. 1978;56(3):341–353.
11.Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG,Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med.2012;366:399–408.
12.Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ.Treatment of disseminated germ-cell tumors with cisplatin,bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435–1440.
13.Bugaut H, Bruchard M, Berger H, Derangère V, Odoul L, Euvrard R, et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS One. 2013;8(6):e65181.
14.Yoshida T, Ogawa M, Ota K, Yoshida Y, Wakui A, Oguro M, et al. Phase II study of NK313 in malignant lymphomas: an NK313 malignant lymphoma study group trial. Cancer Chemother Pharmacol. 1993;31(6):445–448.
15.Lazo JS, Braun ID, Labaree DC, Schisselbauer JC, Meandzija B, Newman RA, et al. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin. Cancer Res. 1989;49(1):185–190.
16.Chen HY, Zheng CY, Zou GL, Xie DX, Gong JP. Peplomycin induces G1-phase specific apoptosis in liver carcinoma cell line Bel-7402 involving G2-phase arrest. Acta Pharmacol Sin.2004;25:1698–1704.
17.Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Haga T, Hashimoto A, et al. Immunomodulatory effects of peplomycin on immunosuppressive and cytotoxic cells in the lesional skin of cutaneous squamous cell carcinoma. Dermatology. 2015;230(3):250–255.
18.Schwartz HS, Grindey GB. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res. 1973;33(8):1837–1844.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Acknowledgment: The authors gratefully acknowledge the PhD, Masuo Hosokawa for supporting their work.
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
Original article
Gong Tian1†,Zhou Guifang1†,Ye Qiumian1,Kuang Jianyuan1,Ou Jinlai2,Xu Zhenxia1,Zhao Wen1,Li Sha1*
1 Department of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou 510632, China
2 Department of Preparation, Sunshinelake Pharma Co., LTD., Shenzhen 523871,China
† Both the authors contributed equally to this work
Address reprint requests to
*Li Sha, Department of Pharmaceutics,College of Pharmacy, Jinan University,Guangzhou 510632, China
Article citation: Tian G, Guifang Z,Qiumian Y, Jianyuan K, Jinlai O, Zhenxia X,Wen Z, Sha L. In vitro anticancer activity of doxorubicin-loading pectin nanoparticles. J Pharm Biomed Sci 2016;06(05):338–342.Available at www.jpbms.info
BSTRACT
By using pectin (PEC) as carrier material and doxorubicin (DOX) as a model drug, the blank PEC nanoparticles (PEC-NPs) and the DOX-loading PEC nanoparticles (DOX-PEC-NPs) were prepared by microemulsification method and drug adsorption. The aim of this study is to investigate the anticancer activity of DOX-PEC-NPs in vitro to understand the advantages of PEC-NPs as an anticancer drug delivery system. The particle size, polydispersity index (PDI) and zeta potential of PEC-NPs were (276.80 ± 2.80) nm, (0.140 ± 0.014) and (−19.83 ± 0.21) mV, while those of DOX-PEC-NPs were (283.73 ± 3.26) nm, (0.157 ± 0.034) and (−18.00 ± 0.44) mV. The entrapment efficiency (EE%) and drug-loading rate (LR%) of DOX-PEC-NPs were (92.10 ± 0.60)% and (18.72 ± 0.10)%, respectively. Using an MTT assay, the DOX-PEC-NPs were proved to greatly inhibit the viability of MDAMB-231 cells, A549 cells and NCI-H1299 cells, and the anticancer activity was higher than that of the DOX solution in these cells. The PEC-NPs had no cytotoxicity against the three tested cells. An inverted fluorescence microscope and flow cytometry were used to observe the intracellular uptake of DOX. The DOX-PEC-NPs resulted in faster and more DOX uptake than DOX solution in the tested cells. The results indicated that the PEC-NPs may be a potential anticancer drug delivery system which could reduce the dose and increase the activity of anticancer drugs.
KEYWORDS doxorubicin, pectin, nanoparticle, anticancer activity.
REFERENCES
1.Hanahan D, Weinberg RA. The hallmarks of cancer. Cell.2000;100:57–70.
2.Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002;2:331–41.
3.Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.
4.Zhang N, Klegerman ME, Deng H, Shi Y, Golunski E, An Z.Trastuzumab–doxorubicin conjugate provides enhanced anticancer potency and reduced cardiotoxicity. J Cancer Ther. 2013;04:308–22.
5.Lei H, Wang X, Wu C. Early stage intercalation of doxorubicin to DNA fragments observed in molecular dynamics binding simulations. J Mol Graph Model. 2012;38:279–89.
6.Evans AR, Miriyala S, St Clair DK, Butterfield DA, Robinson RA.Global effects of adriamycin treatment on mouse splenic protein levels. J Proteome Res. 2012;11:1054–64.
7.Farrell D, Alper J, Ptak K, Panaro NJ, Grodzinski P, Barker AD. Recent advances from the National Cancer Institute Alliance for Nanotechnology in Cancer. ACS Nano. 2010;4:589–94.
8.Raj R, Das S. Prospects of bacteriotherapy with nanotechnology in nanoparticledrug conjugation approach for cancer therapy. Curr Med Chem. 2016;23:1477–94.
9.Spyratou E, Makropoulou M, Mourelatou EA, Demetzos C. Biophotonic techniques for manipulation and characterization of drug delivery nanosystems in cancer therapy. Cancer Lett. 2012;327:111–22.
10.Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer. Br J Cancer. 2007;96:1315–9.
11.Zhuang Y, Deng H, Su Y, He L, Wang R, Tong G, et al. Aptamerfunctionalized and backbone redox-responsive hyperbranched polymer for targeted drug delivery in cancer therapy. Biomacromolecules. 2016 [Epub ahead of print].
12.d’Ayala GG, Malinconico M, Laurienzo P. Marine derived polysaccharides for biomedical applications: chemical modification approaches. Molecules. 2008;13:2069–106.
13.Yuan Q, Venkatasubramanian R, Hein S, Misra RD. A stimulus- responsive magnetic nanoparticle drug carrier: magnetite encapsulated by chitosan-grafted-copolymer. Acta biomater. 2008;4:1024–37.
14.Liu L, Fishman ML, Hicks KB. Pectin in controlled drug delivery: a review. Cellulose. 2006;14:15–24.
15.Katav T, Liu L, Traitel T, Goldbart R, Wolfson M, Kost J. Modified pectin-based carrier for gene delivery: cellular barriers in gene delivery course. J Control Release. 2008;130:183–91.
16.Wen S, Ou J, Luo R, Liang W, OuYang P, Zeng F, et al. Preparation and release behavior of pectin nanoparticles loading doxorubicin. J Pharm Biomed Sci. 2015;5:385–93.
17.Ou J, Hong B, Ye X, Feng C, Gong T, Li S. Preparation and anti-tumor activity of doxorubicin-loading pectin nanoparticles in vitro. J Jinan Univ. 2014;35:330–6.
18.Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycininduced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466–8.
19. Yao F, Duan J, Wang Y, Zhang Y, Guo Y, Guo H, et al. Nanopore single-molecule analysis of DNA-doxorubicin interactions. Anal Chem. 2015;87:338–42.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of support: This research was supported by High Level University Construction Project (88015006).
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.